University Of Texas MD Anderson Cancer Center: PET – FDA 483, Feb 24, 2026
An FDA inspection of University Of Texas MD Anderson Cancer Center: PET in Houston, TX, revealed significant deficiencies across multiple systems. The firm's quality unit failed to adequately oversee production operations, and there were inadequate production and process controls, including unvalidated hold times and insufficient media fill studies. Additionally, facilities were found to be inadequate due to the use of non-sterile disinfectants in critical areas, and batch production records lacked essential equipment identification, collectively posing risks to PET drug quality and sterility.
- Inspection date
- February 24, 2026
- Product type
- drugs
ID · b7ce470a-f71f-426e-8b2d-aa7c9c293ded
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.